Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Subjects
NCT06009237Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of limnetrelvir in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum observed plasma concentration at Day 4, Time to Cmax at Day 4 and 5 more. Started Aug 2023; status: terminated.
02
Drugs
limnetrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06009237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009237.